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Abstract
Wnt signaling plays an important role in developmental and stem cell biology. To test the hypothesis that temporary
inhibition of Wnt signaling will enhance granulation tissue and promote angiogenesis in tissue repair, we employed a
recently characterized small molecule Wnt inhibitor. Pyrvinium is an FDA-approved drug that we identified as a Wnt
inhibitor in a chemical screen for small molecules that stabilize b-catenin and inhibit Axin degradation. Our subsequent
characterization of pyrvinium has revealed that its critical cellular target in the Wnt pathway is Casein Kinase 1a. Daily
administration of pyrvinium directly into polyvinyl alcohol (PVA) sponges implanted subcutaneously in mice generated
better organized and vascularized granulation tissue; this compound also increased the proliferative index of the tissue
within the sponges. To evaluate its effect in myocardial repair, we induced a myocardial infarction (MI) by coronary artery
ligation and administered a single intramyocardial dose of pyrvinium. Mice were evaluated by echocardiography at 7 and 30
days post-MI and treatment; post mortem hearts were evaluated by histology at 30 days. Pyrvinium reduced adverse cardiac
remodeling demonstrated by decreased left ventricular internal diameter in diastole (LVIDD) as compared to a control
compound. Increased Ki-67
+ cells were observed in peri-infarct and distal myocardium of pyrvinium-treated animals. These
results need to be further followed-up to determine if therapeutic inhibition of canonical Wnt may avert adverse
remodeling after ischemic injury and its impact on myocardial repair and regeneration.
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Introduction
Myocardial infarction (MI) is the leading cause of disability and
death in the United States [1]. MI induces cardiomyocyte death
and an inflammatory response that is followed by the formation of
granulation tissue which results in scar formation [2]. The infarct
injury affects the heart in a global manner and incites a process
termed ‘‘ventricular remodeling’’ that affects the size, shape, and
function of the heart and ultimately leads to organ dysfunction [2].
The decline in left ventricular function and adverse remodeling of
the heart typically result in the progression of heart failure.
Current therapies have limited effectiveness on adverse ventricular
remodeling [3].
The non-canonical and canonical Wnt signaling pathways are
indispensible for heart development [4,5] and other biological
processes including cell migration, cell proliferation, development
[6,7], and stem cell self-renewal [8,9]. The central player of the
‘‘canonical’’ pathway is b-catenin, which is maintained at a low
level in the cytoplasm by its association with a destruction
complex. In the absence of Wnt signaling a b-catenin destruction
complex that includes the tumor suppressors adenomatous
polypolis coli (APC) and axin2, interacts with b-catenin [10]
inside the cell. b-catenin gets phosphorylated at serine/threonine
residues 33, 37 and 41 by Casein Kinase-1 and Glycogen Synthase
Kinase-3b (GSK-3b). This results in the recruitment of a b-TrCP-
containing E3 ubiquitin ligase that targets b-catenin for proteo-
somal degradation [11]. However, when the canonical Wnt
signaling is on, the Wnt ligand binds to the frizzled receptor and
LRP co-receptors [12]. This interaction recruits axin2 and
disheveled to the LRP protein and frizzled receptor, respectively
[12,13,14], and further inhibits the kinase activity of the b-catenin
destruction complex [15]. Consequently, b-catenin accumulates
and mobilizes into the nucleus where it interacts with the DNA-
binding proteins of the Tcf/Lef family of high mobility group
(HMG)-box proteins [8,16]. The nuclear Tcf/Lef/b-catenin
complex binds to the DNA and activates the transcription of
Wnt target genes [17,18].
Wnt signaling is quiescent in the adult heart [19]. A recent study
[20,21] in abstract form using Wnt (axin2-LacZ) reporter mice
demonstrated that Wnt signaling is increased post-MI in the
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NIAMS-RO1; Veterans Affairs meritcardiomyocytes of the border zone and remote area between 7–21
days after infarct whereas infiltrating CD45
+ inflammatory cells
showed Wnt activation between 3–7 days post infarct [22]. Hence,
endogenous activation of the Wnt pathway occurs in the heart in
cardiomyocytes and other cells and is evident just prior to the
initiation of the remodeling phase (day 10–26) of murine infarct
repair.
Several genetic models suggest that Wnt inhibition may reduce
adverse remodeling post injury. Transgenic mice in which b-
catenin was downregulated in an a-MHC-restricted manner (i.e.
resulting in lower cardiac Wnt signaling) demonstrated favorable
ischemic remodeling [23]. Mice lacking Dishevelled-1 (resulting in
attenuated Wnt signaling) exhibited decreased hypertrophic
response after pressure overload induced by aortic banding [24].
Other groups reported functional deterioration after injury in mice
expressing a stabilized b-catenin (i.e. activated Wnt signaling) in
cardiomyocytes [25,26]. We and others have shown that
mesenchymal stem cells overexpressing sFRP2, a Wnt inhibitor,
reduced cardiomyocyte apoptosis [27,28]. Taken together, these
studies suggest a role for Wnt inhibition in preventing maladaptive
cardiac remodeling as well as in improved cardiac function after
injury.
Although transgenic animal models of cardiac injury suggest a
role for Wnt inhibition on cardiac repair and regeneration,
pharmacological tools to inhibit Wnt signaling in a cardiac injury
model have not been studied so far. In the present study we
utilized a FDA-approved small molecule inhibitor, pyrvinium,
which inhibits Wnt signaling by directly acting on a downstream
Wnt signaling molecule Casein Kinase-1 to evaluate its therapeutic
effect on wound and cardiac repair and regeneration.
Results
Inhibition of Wnt signaling by pyrvinium
We previously developed a biochemical assay using Xenopus laevis
egg extract that recapitulates Axin and b-catenin turnover in
response to addition of recombinant Wnt co-receptor (LRP6) [29].
Recombinant LRP6 inhibits b-catenin degradation and stimulates
Axin degradation in Xenopus extract. Using a system in which b-
catenin is fused to firefly luciferase and Axin is fused to Renilla
luciferase, we performed a high-throughput screen to identify
small molecules that reverse the effects of recombinant LRP6.
From this screen, we identified a FDA-approved antihelminthic
compound (pyrvinium) that potently inhibits Wnt signaling in
cultured mammalian cells. Pyrvinium inhibited Wnt-mediated
transcription with an EC50 of ,10 nM in contrast to a structurally
related compound (VU-WS211), demonstrated by a luciferase-
based reporter containing TCF/LEF binding sites (TOPflash)
stably transfected in HEK 293 cells (HEK 293 STF) [30]
(Figure 1A). Real-time RT-PCR identified inhibition of endoge-
nous Wnt target genes Myc, Dkk-1, and Axin2 in the presence of
pyrvinium (Figure 1B and Figure S1D, E, and F), consistent with
the effect of pyrvinium on the TOPflash reporter. Based on in vitro
reconstitution studies with purified proteins encoding known Wnt
components, we found that the target of pyrvinium is Casein
Kinase 1a (CK1a). Specificity of pyrvinium binding towards
CK1a was demonstrated in a ligand-binding assay. Pyrvinium has
an intrinsic fluorescent signal. CK1a and GSK3 were dotted on
nitrocellulose and only the nitrocellulose dotted with CK1alpha
showed pyrvinium fluorescence (Figure 1C). To assess the effect of
pyrvinium on CK1a kinase activity, recombinant CK1a was
incubated with [c
32P]ATP and casein in the presence or absence
of pyrvinium. Phosphorylation of casein by CK1a was enhanced
in the presence of pyrvinium indicated that pyrvinium activated
CK1a kinase activity (Figure 1D). The predominant cytoplasmic
effects of CK1a activation by pyrvinium in the Wnt pathway were
to promote degradation of b-catenin and to inhibit Axin
degradation. Indeed, immunoblot analysis of cytoplasmic prepa-
rations of HEK293 cells treated with increasing concentrations of
pyrvinium demonstrated dose-dependent decreased and increased
levels of b-catenin and Axin, respectively (Figure 1E and Figure
S1A and B). Moreover, in the nucleus, pyrvinium promoted the
degradation of Pygopus, a nuclear factor associated with the
activation of a Wnt transcriptional program (Figure 1F and Figure
S1C). Taken together, these results demonstrate that pyrvinium
inhibits Wnt signaling. A detailed description of our identification
of pyrvinium and the characterization of its mechanism of action
will be presented elsewhere [31].
Pyrvinium increases granulation tissue organization,
proliferation, and vascularity in the sponge model of
tissue repair
The PVA sponge model is used to study granulation tissue
deposition that mimics healing by secondary intention [32,33].
The effects of pyrvinium on granulation tissue organization,
proliferation, and vascularization were analyzed and compared
among the sponges implanted in multiple animals. Sponges
injected with pyrvinium showed better granulation tissue organi-
zation when compared with its molecular analog, VU-WS211
(referred to as compd 211) (Figure 2A). The molecular analog of
pyrvinium, compd 211, does not inhibits Wnt signaling [31];
hence used as a control. The tissue deposited within the sponges
treated with compd 211 was less organized with poor architecture.
The effect of pyrvinium-induced Wnt inhibition on cellular
proliferation and tissue vascularity were assessed by anti-Ki-67
and anti-PECAM-1 staining, respectively. A significant increase in
proliferation was evident in the sponges treated with pyrvinium
(Figure 2A and 2B). In addition, anti-PECAM-1 immunostaining
demonstrated that sponges treated with pyrvinium were better
vascularized when compared with the sponges treated with compd
211 (Figure 2A and 2C). Taken together, these results demonstrate
a positive correlation between pyrvinium treatment and tissue
organization, proliferation, and vascularity during granulation
tissue formation.
Pyrvinium prevents adverse cardiac remodeling and
increases proliferation in the injured myocardium
To evaluate pyrvinium-mediated myocardial regeneration, we
assessed the therapeutic effect of pyrvinium in a mouse model of
myocardial infarction. Myocardial infarcts were induced in mice
by left coronary artery ligation, which produced infarcts in the
anterolateral wall of the left ventricle (LV). Ten minutes after
ligation, 200 nM of pyrvinium or compd 211 was injected at the
junction of viable and infarcted tissue. Whereas no toxicity was
observed when pyrvinium was injected subcutaneously into
implanted sponges, a high number of mice (13 out of 22 animals)
treated with intracardiac pyrvinium experienced lethal toxicity
and died within the first 24 hours. Those that survived beyond the
first 48 hours demonstrated similar activity and growth pattern as
the control animals. Toxicity associated with pyrvinium was
anticipated as IV or IP injection of pyrvinium at levels high
enough to achieve Wnt-inhibitory plasma levels resulted in death
within 24–48 hours in most mice (data not shown). This restricted
our treatment regimen to a one-time intracardiac injection.
Masson trichrome-stained sections of hearts (Figure 3A) from
mice 30 days after experimental infarct and treatment with
pyrvinium or compd 211 showed no difference in the infarct size,
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wall (Figure 3B). Ventricular remodeling and cardiac function
were analyzed by echocardiography at 7 and 30 days post MI. LV
internal dimension diastolic (LVIDD) and LV internal dimension
systolic (LVIDS) reflect remodeling of the infarcted ventricle
(Figure 3C). The percentage difference in LVIDD between day 7
and day 30 was significantly reduced in animals receiving
pyrvinium when compared with the control compd 211;
29.8063.79 vs. 5.9665.03 (p=0.0273) (Table 1). Additionally,
the percentage difference in LVIDS between day 7 and day 30 was
reduced in animals treated with pyrvinium when compared with
compd 211; 215.965.13 vs. 20.854610.2; the data however was
not statistically significant. Moreover, the percentage difference
analysis of other echocardiogram parameters, such as interven-
tricular wall thickness in diastole and systole (IVSD and IVSS), LV
posterior wall thickness in systole (LVPWS) demonstrated a trend
towards favorable heart remodeling (Figure S2 and Table 1). To
determine whether pyrvinium improved cardiac function, the
percentage differences in fractional shortening (FS) between 7 and
30 days after treatment were analyzed (Figure 3D). The average
difference in fractional shortening of pyrvinium-treated vs. compd
211 control animals between days 7 and 30 was 16.966.19 vs.
20.9612.4 (p.0.05). This observation, along with the absence of
functional or anatomic difference between the two cohorts at day
7, provides greater evidence that pyrvinium did not acutely affect
the extent of the infarct.
The identification both in genetic models [23,24] as well as in
our study that Wnt inhibition diminishes adverse post-infarct
remodeling as well as the enhanced proliferation observed in
sponge granulation tissue directed us to investigate if pyrvinium
mediated Wnt inhibition can increase cardiomyocyte survival by
enhancing cardiomyocyte proliferation. To assess proliferation, we
analyzed the tissue with Ki-67, a nuclear protein necessary for
cellular proliferation [34]. Pyrvinium treatment led to increased
Ki-67
+ staining of cells in the peri-infarct and distal myocardium
(Figure 4A and 4B). Interestingly, vascular density within the
myocardial scar, as identified by PECAM-1 staining, was not
affected by pyrvinium treatment (Figure 4C). However, the
numbers of active caspase-3
+ cells, which reflect cells undergoing
apoptosis, were not statistically different between pyrvinium and
compd 211 treated myocardium (Figure S3).
We determined whether pyrvinium specifically increased cardio-
myocyte mitosis utilizing an anti-phospho histone-3 antibody.
Phosphorylation of histone 3 (pH3) on Ser 10 is an established
cellular marker for chromosome condensation during mitotic
prophase [35,36]. We immunostained the distal myocardium using
anti-pH3 and performed confocal microscopy to assess the effect of
Wnt inhibition on the mitotic status of cardiomyocytes. pH3
+
(red) cardiomyocytes exhibited a differentiated phenotype as
indicated by striations and expression of a-sarcomeric actin (green)
(Figure 4D). Reconstruction of optical sections enabled us to assign
pH3
+ nuclei unequivocally to cardiomyocytes (side panel). pH3
+
Figure 1. Pyrvinium inhibits Wnt signaling. (A) Pyrvinium inhibits TOPflash activation with an EC50 of ,10 nM in contrast to the structurally
related compound VU-WS211. HEK 293 STF (TOPflash) luciferase reporter cells incubated with Wnt3a-conditioned media were treated as indicated.
Graph represents mean 6 SEM of TOPflash signal normalized to cell number (performed in quadruplicate). (B) Pyrvinium (100 nM) decreases
transcript levels of endogenous Wnt target genes Myc, Dkk-1, and Axin2 as assessed by real-time PCR. GAPDH is control. (C) Pyrvinium binds CK1a in
vitro. CK1a and GSK3 (0.5 mg each, in duplicates) were spotted on nitrocellulose, incubated with pyrvinium (10 nM), and bound pyrvinium detected
based on its fluorescent property. (D) Pyrvinium stimulates CK1a activity. CK1a (100 nM) was incubated with recombinant casein (100 nM) plus or
minus pyrvinium (10 nM) in a kinase reaction containing [c
32P]ATP followed by SDS-PAGE and exposure to PhosphoImager screen. (E) Pyrvinium
decreases and increases intracellular b-catenin and Axin levels, respectively. HEK 293 cells were treated for 16 hours as indicated, and cytoplasmic
preparations were immunoblotted for b-catenin and Axin. b-tubulin is loading control. (F) Pyrvinium decrease steady-state levels of Pygopus. HEK
293 STF cells expressing HA-tagged human Pygopus-2 were treated with pyrvinium as indicated. Lysates were immunoblotted for HA. b-
galactosidase (b-gal) is transfection control.
doi:10.1371/journal.pone.0015521.g001
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treated hearts. These results indicate that a one-time pyrvinium
injection is sufficient to increase proliferation of differentiated
cardiomyocytes in the remote myocardium and promote favorable
cardiac remodeling, albeit without a significant improvement in
cardiac function or size of infarct.
Discussion
Wnt signaling has been shown to be a major regulator of
cardiogenesis [37,38,39]. Prior to gastrulation, Wnt/b-catenin
signaling promotes cardiac differentiation whereas signaling
during gastrulation inhibits heart formation [37,38,39]. Consistent
with these studies, early treatment of mouse embryonic stem cells
with Wnt3a stimulates mesoderm induction whereas late Wnt3a
stimulation inhibits cardiac differentiation [40]. Furthermore, the
Wnt inhibitors Dickkopf-1 (Dkk-1) and secreted frizzled-related
proteins (sFRPs) have been shown to induce cardiac differentiation
of stem cells [4,37,39]. These studies clearly demonstrate the
importance of Wnt signaling in cardiac development. Additionally,
gene expression profiling performed after myocardial infarct
showed post-injury activation of Wnt signaling suggesting the role
of Wnt signaling in cardiac repair [20].
Several antagonists of the Wnt pathways have been character-
ized [41]. One class, including sFRPs, binds and sequesters Wnt to
inhibit both canonical and non-canonical Wnt signaling [41].
Fusion of Frizzled8-cysteine rich domain (binds Wnt) to the
human Fc domain inhibited Wnt signaling and teratocarcinoma
growth in mice but has not been widely used in vivo possibly due to
its low in vivo efficacy or issues of selectivity [42]. The Dkk class
inhibits canonical Wnt signaling by binding to LRP5/LRP6 of the
Wnt receptor complex [41]. Recently a novel class of small
molecule Wnt inhibitors has been identified that act by inhibiting
tankyrase, a poly (ADP-ribose) polymerase [43,44].
We recently have identified a FDA-approved drug, pyrvinium,
as a potent inhibitor of Wnt signaling that acts by binding and
activating CK1a [31]. Daily administration of pyrvinium by
injection into PVA sponges, implanted subcutaneously, generated
granulation tissue that was more cellular/proliferative, significant-
ly better vascularized and with better tissue organization.
Figure 2. Pyrvinium increases granulation tissue organization, proliferation, and vascularity in the sponge model of tissue repair.
(A) Representative images of the pyrvinium- and compd 211-treated sponges stained with H&E to assess organization of the granulation tissue, anti-
Ki-67 to analyze proliferation, and anti-PECAM-1 to assess vascular density of the sponge granulation tissue. SP=sponge matrix, arrows point at
positive stain. (B) Proliferation graphed as number of Ki-67 positive cells/total tissue area and (C) vascular density graphed as percentage of
immunopositive PECAM-1 area/total tissue area in histologic sections from granulation tissue. Data represents averages of multiple 40x fields from
unpaired samples (n=6). The statistical significance between experimental groups and control was determined by Mann Whitney Test, p,0.05 was
considered statistically significant.
doi:10.1371/journal.pone.0015521.g002
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Wnt inhibitor in cardiac injury. Pyrvinium-treated mice demon-
strated significantly more favorable LV remodeling 30 days post-
MI compared to a control compound. Cardiac remodeling is a
physiological response and a compensatory change in the
structure and function of the heart in response to cardiac injury
or other pathological conditions. Although, early remodeling is
an adaptive response to maintain cardiac function, it progres-
sively becomes maladaptive and results in the progression of
cardiovascular diseases. Therefore, identification of a therapeutic
inhibitor to help prevent the process of adverse cardiac
remodeling is highly desirable. Remarkably, peri-infarct intra-
muscular administration of pyrvinium prevented adverse cardiac
remodeling and this effect was observed after only a single dose of
intramuscular administration of the Wnt inhibitor following
injury. Because we were limited to a single intramuscular
administration of pyrvinium after injury, we are unable to
confidently assess the effect of Wnt inhibition on cardiac
function/infarct size. Nonetheless, mice that survived after the
pyrvinium treatment showed favorable cardiac remodeling after
MI, indicating the efficacy of a pharmaceutical Wnt inhibitor in
the prevention of adverse cardiac remodeling.
To better understand the basis for how therapeutic Wnt
inhibition might affect cardiac remodeling, we tested whether
pyrvinium affected cellular apoptosis in both PVA granulation
tissue and in infarcted myocardium. We did not observe any
statistically significant differences in level of cellular apoptosis by
analyzing the numbers of activated caspase-3 positive cells in
pyrvinium treated animals as compared to those treated with
control compound (Figure S3). Prevention of cell loss by apoptosis
as a result of inhibition of caspase activation through therapeutic
interventions can protect cardiac function [45]. In myocardial
ischemia/reperfusion-induced injury the non-specific inhibition of
caspases may be of therapeutic benefit [46]. Multiple in vivo and ex
vivo models have correlated the quantity of apoptotic cell numbers
with the cardiac function and infarct size indicating the
significance of apoptosis during and after cardiac injury [47,48].
Although determination of absolute values of apoptosis would
require the combination of several techniques and limiting analysis
of myocardial tissue at 30 days post infarct may have missed any
short term effects on apoptosis, these data suggest that apoptosis is
unlikely to account for the observed phenotype.
In granulation tissue formation within both PVA sponges and
infarcted hearts, Ki-67
+ cells were significantly increased with
pyrvinium treatment. Increased cardiomyocyte DNA synthesis
evident by Ki-67
+ cells in both the border zone and remote area
suggested that some differentiated cardiomyocytes re-enter the cell
cycle, which we further confirmed by co-localizing a mitotic
marker (anti-pH3) with a myocyte protein. Interestingly, we did
not observed any difference in the vascularization of the infarcted
heart treated with pyrvinium when compared with the control
compd 211. This observation supports our conclusion that
increased proliferation in pyrvinium-treated heart cells is not
due to better vascularization but due to direct inhibition of
Wnt signaling in cardiomyocytes. While we have shown that
a subpopulation of differentiated cardiomyocytes has prolifera-
tive potential, our results do not exclude the possibility that
pyrvinium-mediated Wnt inhibition may have multifactorial
impact that contribute to the observed favorable post-injury
global remodeling.
Figure 3. Pyrvinium prevents adverse myocardial remodeling. (A) Representative Masson trichrome-stained sections of hearts from mice 30
days after experimental infarct and treatment with pyrvinium and/or compd 211. Arrows point at the scarred ventricular wall. L=lumen. (B) The
infarct size was quantified as the percentage of the left ventricular wall that exhibited myocyte replacement by scar. (C) LVIDD and LVIDS to represent
cardiac remodeling, and (D) fractional shortening, as a measurement of cardiac function, were determined by echocardiography and are plotted as
percentage difference values (mean +/2 SEM) between 7 and 30 days after infarct. The statistical significance between experimental groups and
control was determined by unpaired t-test (n=6 for compd 211 and n=7 for pyrvinium).
doi:10.1371/journal.pone.0015521.g003
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the development of therapeutic reagents. Our study indicated that a
pharmacologic Wnt inhibitor may be a promising tool to promote
tissue repair and prevent adverse cardiac remodeling. Understand-
ing the therapeutic value of Wnt inhibition in cardiac injury using
pyrvinium is limited by its toxicity. Yet, the basis for pyrvinium’s
toxicity, as well as that of other small molecular Wnt inhibitors is not
clearly established. Pyrvinium regulates Wnt signaling by activating
CK1a and regulating the stabilization of b-catenin and Axin in the
cytoplasm. The CK1a family of serine/threonine kinases is
evolutionarily conserved in eukaryotes and is associated with a wide
range of cellular processes that includes cell cycle, apoptosis, and
Wnt signaling [49]. It is not clear whether the toxicity that is
associated with pyrvinium is due to its effects on CK1a or to its
potential alkylating activity (data not shown). Nonetheless, our
studieshavedemonstratedthepossibilityofutilizingasmallmolecule
Wnt inhibitor as a curative agent due to its ability to positively affect
wound repair and regeneration both in vitro and in vivo. Therefore,
despite the limitations resulting from in vivo toxicity, these findings
highlight the potential of Wnt inhibition to treat MIand the need for
a safe and effective therapeutic Wnt inhibitor to better dissect the
effect of Wnt inhibition on cardiac repair and regeneration. Our
ongoing studies are to characterize newly identified small molecule
Wnt inhibitors as well as antibody based inhibitors to better define
and understand the mechanistic basis for adverse effects of systemic
Wnt inhibition. Identification of a non-toxic Wnt inhibitor will
enable us to more rigorously test the utility of Wnt inhibitors as
therapeutic agents to enhance repair and regeneration.
Materials and Methods
Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Vanderbilt University Institutional
Animal Care and Use Committee (Protocol Number: M/07/236).
All experiments were performed using appropriate analgesics and
anesthetics, and every effort was made to minimize pain/distress.
Antibodies and Reagents
Antibodies against specific antigens were purchased as follow-
ing: CD31/platelet endothelial cell adhesion molecule-1 (PECAM-
1; clone 557355, PharMingen), Ki-67 (Novocastra Labs,
NCLKi67p), phospho histone-3 (Millipore). a-sarcomeric actin
(Sigma), b-catenin (BD Transduction Labs), Axin1 (R&D
Antibodies), b-tubulin (Santa Cruz), HA 3F10 (Roche), and b-
galactosidase (Promega). Appropriate secondary antibodies were
purchased from Jackson ImmunoResearch, Santa Cruz, and
Molecular Probes. 4’,6-diamidino-2-phenylindole (DAPI) was
purchased from Vector laboratories Inc. Recombinant Wnt3a
was purchased from (R&D). Recombinant human CK1a and
GSK3 were purchased form Invitrogen. Casein was purchased
from Sigma (C8032). Pyrvinium chloride and VU-WS211 were
synthesized by the Vanderbilt Institute of Chemical Biology’s
medicinal chemistry core. DMSO was used as a vehicle for
pyrvinium in all experiments unless otherwise stated.
Cell lines
HEK 293 STF was a gift from Jeremy Nathans. Wnt3a cells
were purchased from ATCC. Cells were maintained in DMEM,
10% fetal bovine serum (FBS), and antibiotics. Cells were treated
with compounds and/or Wnt for 24 hours unless otherwise stated.
Reporter assays
For cell-based luciferase assays, HEK 293 STF cells were seeded
into 96-well plates at sub-confluent levels and luciferase activities
measured by Steady-Glo Luciferase Assay (Promega). Luciferase
activities were normalized to viable cell number using the
CellTiter-Glo Assay (Promega). All graphs were made in Prism
4 (GraphPad Software, inc.) with nonlinear regression fit to a
sigmoidal dose-response curve (variable slope). Wnt3a and
pyrvinium were added 24 hours after transfection for an
additional 24 hours.
Dot blot and kinase assay
For ligand dot blot assay, purified proteins CK1a and GSK3
(0.5 ug protein each) were dotted on nitrocellulose membranes
and blocked for 1 hour using 5% milk in TBS. Pyrvinium was then
added and incubated for 3 hours at 23uC. Membrane was then
washed three times for 5 minutes in TBS plus 0.1% Tween-20.
The pyrvinium fluorescence image was acquired on a Xenogen
IVIS 200 using excitation 500-550 and emission 575-650 spectrum
fluorescence settings. In vitro kinase assay was performed as
previously described [29].
RNA isolation, cDNA synthesis, and real-time PCR
Total RNA was isolated from HEK 293 cells 24 hours after
pyrvinium treatment using RNAeasy RNA extraction kit (Qiagen),
and cDNA generated using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, ABI). Real-time PCR
assays were performed in quadruplicate using TaqMan Gene
Table 1. Pyrvinium improves cardiac remodeling.
Echocardiogram
parameters Compd 211 Pyrvinium
LVIDD, cm d7 0.34160.0195 0.35760.0162
d30 0.35660.00733 0.32060.0133
LVIDS, cm d7 0.21860.0255 0.23860.0170
d30 0.20560.00790 0.19760.0140
IVSD, cm d7 0.072360.00596 0.077960.00517
d30 0.076860.00285 0.073760.00240
IVSS, cm d7 0.10660.00760 0.11560.0119
d30 0.11860.00448 0.11060.00480
LVPWD, cm d7 0.066560.00437 0.064960.00550
d30 0.056560.00426 0.056960.00152
LVPWS, cm d7 0.084260.00333 0.08860.00558
d30 0.088760.00464 0.076160.00328
FS d7 37.063.77 33.662.67
d30 42.661.25 38.762.08
EJ d7 0.72660.0476 0.68860.0353
d30 0.79960.0132 0.75360.0275
DLVIDD, % 5.9665.03 29.8063.79*
DLVIDS, % 20.854610.2 215.965.13
DFS, % 20.9612.4 16.966.19
The top eight rows represent the mean and standard error of mean (6 SEM)
values for each treatment at day 7 and day 30. The mean 6 SEM percentage
difference (D%) values are in the bottom three rows. The statistical significance
between experimental groups and control was determined by unpaired t-test
(n=6 for compd 211 and n=7 for pyrvinium).
*p,0.05 211 vs. pyrvinium.
doi:10.1371/journal.pone.0015521.t001
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e15521Figure 4. Pyrvinium promotes proliferation of myocytes in the peri-infarct and distal areas of the injured heart. (A and B)
Representative images of anti-Ki-67 stained sections of compd 211- and pyrvinium-treated myocardium and the distal myocardium following MI. (A
and B) Proliferation graphed as percentage of immunopositive Ki-67 positive cells/20x field in histologic sections from the proximal and the distal
infarcted heart. (C) Representative images of anti-PECAM-1 staining to designate vascular density among experimental cohorts. Arrows point towards
positive stain. Graph demonstrating the difference in PECAM-1 positive area/40x field. Data represents averages of multiple fields from unpaired
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probes (ABI) and an ABI 7000 sequence detection system.
Repair/Granulation Tissue Stimulation
For repair/granulation tissue stimulation model, PVA sponge
discs (4 mg, 2 mm height, 4 mm diameter) were presoaked with
40 ml of matrigel and implanted subcutaneously in adult mice.
Two sponges were implanted in each mouse and three mice were
used per treatment. Following ten days of sponge implantation
mice were injected with either 200 nM pyrvinium or compd 211
(in 40 ml PBS per injection) every day or every other day, receiving
nine injections in total. Twenty one day after sponge implantation
animals were taken down. The sponges were fixed in 10% neutral
buffered formalin and stored at 280uC until use.
Myocardial Infarction
For MI model, C57Bl6 mice were anesthetized with sodium
pentathol (50 mg/kg) and endotracheal intubation was performed
under direct laryngoscopy. Mice were ventilated with a small
animal respirator (tidal volume =1.0 ml, rate =110 breaths/
min). With the use of a surgical microscope, a left thoracotomy was
performed. The fourth intercostal space was entered using scissors
and blunt dissection. A 7-0 silk suture was placed through the
myocardium into anterolateral LV wall (around the left anterior
descending artery) and the artery ligated. Continuous EKGs were
obtained during the procedure. 200 nM of pyrvinium or compd
211 in 25 mL of PBS were injected into the peri-infarct area. The
chest was closed in layers with 6-0 silk (6-0 nylon to close the skin)
and the animal was gradually weaned from the respirator to avoid
complicating pneumothorax. Cardiac dimensions were obtained
from 2-D guided M-mode images (100 frames/sec) and were read
blinded using short axis and a parasternal long-axis views with the
leading edge method. All measurements were done on unsedated
mice. Measurements were averaged over 3 consecutive beats from
the LV posterior wall (LVPW) the interventricular septum (IVS)
and LV internal diameter (LVID). Fractional shortening (FS) and
ejection fraction (EF) were obtained at day 7 and day 30 post MI.
Excised hearts were immersion-fixed in 10% buffered formalin for
24 hours and transferred to 70% ethanol to obtain serial sections
in order to measure the infarct size. Subsequently, serial sections
through the ventricles were obtained parallel to the atrioventric-
ular groove and the samples were processed for light microscopy.
Paraffin sections were stained with H & E and Masson trichrome.
In order to measure the infarcted areas in all sections on
trichrome-stained slides, the percentage of left ventricle that
exhibits myocyte replacement by scar was quantified using Image
Pro software (Media Cybernetics) [50].
Histochemistry and Morphometry
PVA Sponges were embedded with cut surface down for
histology. Immunohistochemistry for PECAM-1 to analyze
vascularity and Ki-67 to identify proliferation was performed as
described by Young et al [51,52]. A CoolSNAP Hq CCD camera
(Photometrics) was utilized to obtain the images of PECAM-1
stained sections. Around 10 digital images from each section were
acquired at defined magnification (406) at random for vascular
density. The area of tissue for each field was quantified using
MetaMorph (Molecular Devices) by outlining tissue and calculat-
ing total area per field. For Ki-67 analysis, around 10 digital
images were taken at random from each section at specific
magnification (406). The images were acquired with a digital
camera (Pixera, Los Gatos, CA). and positively stained cells were
counted manually.
Confocal Microscopy
Paraffin-embedded cardiac tissue slides were deparaffinized,
blocked in 10% goat serum for one hour and co-stained with anti-
alpha sarcomeric actin and phospho-histone-3 antibodies over-
night at 4uC. The slides were washed in PBS and co-stained with
goat anti-mouse and goat anti-rabbit secondary antibodies for two
hours, washed in PBS, and mounted with DAPI. For confocal
analysis, LSM510 (Zeiss) microscope was used to capture 1 mm
optical slices (z stack); the images were analyzed with Metamorph
v5.0 (Universal Imaging Corp.).
Statistical Analysis
The statistical significance between experimental groups and
control was determined by unpaired Student’s t-test, Mann
Whitney Test, or ANOVA followed by Newman-Keuls post- test
as designated using GraphPad Prism. p,0.05 was considered
statistically significant.
Supporting Information
Figure S1 Pyrvinium inhibits Wnt signaling. (A and B)
Pyrvinium decreases and increases intracellular b-catenin (*,
**p,0.005, t-test) and Axin (*p,0.05, **p,0.005, t-test) levels,
respectively. HEK 293 cells were treated for 16 hours as indicated,
and cytoplasmic preparations were immunoblotted for b-catenin
and Axin. Quantification of the relative cytoplasmic b-catenin
protein levels normalized to b-tubulin; n=5. (C) Pyrvinium
decrease steady-state levels of Pygopus. HEK 293 STF cells
expressing HA-tagged human Pygopus-2 were treated with
pyrvinium as indicated. Lysates were immunoblotted for HA.
Quantification of the relative pygopus levels normalized to b-
galactosidase (b-gal) (*, **p,0.005, t-test); n=5. Quantitation of
immunoblots were performed by scanning images with Adobe
Photoshop CS4 (Adobe Systems) and the intensity of the bands
quantified with NIH Image J with correction for background. (D,
E, and F) Pyrvinium (100 nM) decreases transcript levels of
endogenous Wnt target genes Myc, Dkk-1, and Axin2 as assessed
by real-time PCR. Relative transcript levels normalized to
GAPDH (*p,0.05, **p,0.005, t-test); n=3.
(TIF)
Figure S2 Pyrvinium prevents adverse myocardial
remodeling. LVPWS, LVPWD, IVSD, and IVSS to represent
cardiac remodeling, and ejection fraction, as a measurement of
cardiac function, were determined by echocardiography and are
plotted as percentage difference values (mean +/2 SD) between 7
and 30 days after infarct. The statistical significance between
experimental groups and control was determined by unpaired t-
test.
(TIF)
Figure S3 Pyrvinium treatment does not affect cellular
apoptosis. Representative images of the pyrvinium- and compd
211-treated sponges stained with anti-caspase-3 and histological
samples (n=6). (D) Representative immunostained confocal images of the sections of remote myocardium co-stained with anti-pH3 (1:50; red) for
cells undergoing mitosis, anti-alpha sarcomeric actin (1:500; green) for cardiac muscles, and DAPI (blue) for the nuclei; yz axis designates anti-pH3 and
anti-alpha sarcomeric actin co-staining. The statistical significance between experimental groups and control was determined by one way ANOVA
with Newman-keuls post-test.
doi:10.1371/journal.pone.0015521.g004
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treated myocardium following MI. SP=sponge matrix, arrows
point at positive stain.
(TIF)
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